Literature DB >> 33163523

Hepatocellular carcinoma chemoprevention in chronic hepatitis B patients: all-in on statins?

José Ursic-Bedoya1, Boris Guiu2.   

Abstract

Entities:  

Year:  2020        PMID： 33163523      PMCID： PMC7603923          DOI： 10.21037/hbsn.2020.03.06

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  12 in total

1.  Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.

Authors:  Myung Ji Goh; Dong Hyun Sinn; Seonwoo Kim; Sook Young Woo; Hyun Cho; Wonseok Kang; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik
Journal:  Hepatology       Date:  2020-02-14       Impact factor: 17.425

2.  Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population.

Authors:  Jonggi Choi; Seungbong Han; Namkug Kim; Young-Suk Lim
Journal:  Hepatology       Date:  2017-10-11       Impact factor: 17.425

3.  Anti-inflammatory effect of pitavastatin on NF-kappaB activated by TNF-alpha in hepatocellular carcinoma cells.

Authors:  Juyong Wang; Takashi Tokoro; Susumu Higa; Isao Kitajima
Journal:  Biol Pharm Bull       Date:  2006-04       Impact factor: 2.233

4.  Atorvastatin Decreases HBx-Induced Phospho-Akt in Hepatocytes via P2X Receptors.

Authors:  Aram Ghalali; Javier Martin-Renedo; Johan Högberg; Ulla Stenius
Journal:  Mol Cancer Res       Date:  2017-02-16       Impact factor: 5.852

Review 5.  Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis.

Authors:  Siddharth Singh; Preet Paul Singh; Abha Goyal Singh; Mohammad Hassan Murad; William Sanchez
Journal:  Gastroenterology       Date:  2012-10-12       Impact factor: 22.682

Review 6.  Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.

Authors:  Giovanna Fattovich; Flavia Bortolotti; Francesco Donato
Journal:  J Hepatol       Date:  2007-12-04       Impact factor: 25.083

7.  Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  James H Lewis; Mary Ellen Mortensen; Steven Zweig; Mary Jean Fusco; Jeffrey R Medoff; Rene Belder
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

8.  High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load.

Authors:  Tai-Chung Tseng; Chun-Jen Liu; Hung-Chih Yang; Tung-Hung Su; Chia-Chi Wang; Chi-Ling Chen; Stephanie Fang-Tzu Kuo; Chen-Hua Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Gastroenterology       Date:  2012-02-11       Impact factor: 22.682

Review 9.  Chronic hepatitis B virus infection.

Authors:  Wai-Kay Seto; Ying-Ru Lo; Jean-Michel Pawlotsky; Man-Fung Yuen
Journal:  Lancet       Date:  2018-11-24       Impact factor: 79.321

Review 10.  Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.

Authors:  Naoto Fujiwara; Scott L Friedman; Nicolas Goossens; Yujin Hoshida
Journal:  J Hepatol       Date:  2017-10-06       Impact factor: 30.083
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.